Li Maozhong, Cong Bingbing, Wei Xiaofeng, Wang Yiting, Kang Lu, Gong Cheng, Huang Qi, Wang Xin, Li You, Huang Fang
Beijing Center for Disease Prevention and Control, Beijing Academy for Preventive Medicine, Beijing Institute of Tuberculosis Control Research and Prevention, Beijing, 100013, People's Republic of China.
Beijing Research Center for Respiratory Infectious Diseases, Beijing, 100013, People's Republic of China.
Lancet Reg Health West Pac. 2024 Mar 27;45:101050. doi: 10.1016/j.lanwpc.2024.101050. eCollection 2024 Apr.
Respiratory syncytial virus (RSV) has posed substantial morbidity and mortality burden to young children and older adults globally. The coronavirus disease 2019 (COVID-19) pandemic was reported to have altered RSV epidemiology and could have important implications for RSV prevention and control strategies. We aimed to compare RSV epidemiology in different phases of the COVID-19 pandemic with the pre-pandemic period by leveraging epidemiological, molecular, and serological data collected from a prospective respiratory pathogen surveillance and serology study.
This study was based on the data during July 1, 2015 to November 30, 2023 from the Respiratory Pathogen Surveillance System (RPSS), a sentinel-hospital based surveillance system of acute respiratory infections consisting of 35 hospitals that represent residents of all ages from all 16 districts in Beijing, China. RSV infection status was tested by RT-PCR and gene sequencing and phylogenetic analysis was conducted among the identified RSV strains. We further supplemented RPSS data with three serology surveys conducted during 2017-2023 that tested RSV IgG levels from serum specimens. RSV detection rate was calculated by calendar month and compared across RSV seasons (defined as the July 1 through June 30 of the following year). RSV IgG positivity proportion was calculated by quarter of the year and was correlated with quarterly aggregated RSV detection rate for understanding the relationship between infection and immunity at the population level.
Overall, a total of 52,931 respiratory specimens were collected and tested over the study period. RSV detection rates ranged from 1.24% (94/7594) in the 2017-2018 season to 2.80% (219/7824) in the 2018-2019 season, and from 1.06% (55/5165) in the 2022-2023 season to 2.98% (147/4938) in the 2021-2022 season during the pre-pandemic and pandemic period, respectively. ON1 and BA9 remained the predominant genotypes during the pandemic period; no novel RSV strains were identified. RSV circulation followed a winter-months seasonal pattern in most seasons. One exception was the 2020-2021 season when an extensive year-round circulation was observed, possibly associated with partial relaxation of non-pharmaceutical interventions (NPIs). The other exception was the 2022-2023 season when very low RSV activity was observed during the usual winter months (possibly due to the concurrent local COVID-19 epidemic), and followed by an out-of-season resurgence in the spring, with RSV detection persisting to the end of the study period (November 2023). During the two seasons above, we noted an age-group related asynchrony in the RSV detection rate; the RSV detection rate in young children remained similar (or even increased with borderline significance; 43/594, 7.24%, and 42/556, 7.55% 292/5293, 5.52%; = 0.10 and = 0.06, respectively) compared with the pre-pandemic seasons whereas the detection rate in older adults decreased significantly (8/1779, 0.45%, and 3/2021, 0.15% 160/10,348, 1.55%; < 0.001 in two comparisons). Results from serology surveys showed significantly declined RSV IgG positivity in the 2022-2023 season compared to the pre-pandemic seasons (9.32%, 29/311 vs 20.16%, 100/496; < 0.001); older adults had significantly higher RSV IgG positivity than young children in both pre-pandemic and pandemic periods ( values < 0.001).
Our study documented the trajectory of RSV detection along with the changes in the stringency of NPIs, measured IgG positivity, and local COVID-19 epidemics. The findings suggest the interplay between contact patterns, immunity dynamics, and SARS-CoV-2 infection in shaping the RSV epidemics of population of different ages. These findings provide novel insights into the potential drivers of RSV circulating patterns and have important implications for RSV prevention and control strategies.
The High-qualified Public Health Professionals Development Project, Capital's Funds for Health Improvement and Research, and the Public Health Personnel Training Support Program.
呼吸道合胞病毒(RSV)在全球范围内给幼儿和老年人带来了巨大的发病和死亡负担。据报道,2019年冠状病毒病(COVID-19)大流行改变了RSV的流行病学特征,可能对RSV的预防和控制策略产生重要影响。我们旨在通过利用一项前瞻性呼吸道病原体监测和血清学研究收集的流行病学、分子和血清学数据,比较COVID-19大流行不同阶段与大流行前时期的RSV流行病学特征。
本研究基于2015年7月1日至2023年11月30日期间来自呼吸道病原体监测系统(RPSS)的数据,该系统是一个基于定点医院的急性呼吸道感染监测系统,由35家医院组成,代表了中国北京16个区所有年龄段的居民。通过逆转录聚合酶链反应(RT-PCR)检测RSV感染状况,并对鉴定出的RSV毒株进行基因测序和系统发育分析。我们还通过2017 - 2023年期间进行的三项血清学调查对RPSS数据进行补充,这些调查检测了血清标本中的RSV IgG水平。按日历月计算RSV检出率,并在RSV流行季节(定义为7月1日至次年6月30日)进行比较。按年份季度计算RSV IgG阳性比例,并将其与季度汇总的RSV检出率相关联,以了解人群层面感染与免疫之间的关系。
总体而言,在研究期间共收集并检测了52,931份呼吸道标本。在大流行前和大流行期间,RSV检出率在2017 - 2018季节为1.24%(94/7594),在2018 - 2019季节为2.80%(219/7824),在2022 - 2023季节为1.06%(55/5165),在2021 - 2022季节为2.98%(147/4938)。在大流行期间,ON1和BA9仍然是主要基因型;未发现新的RSV毒株。在大多数季节,RSV的传播遵循冬季季节性模式。一个例外是2020 - 2021季节,观察到全年广泛传播,可能与非药物干预(NPIs)部分放宽有关。另一个例外是2022 - 2023季节,在通常的冬季月份观察到RSV活动非常低(可能由于当地同时发生的COVID-19疫情),随后在春季出现季节性外的回升,RSV检测一直持续到研究期结束(2023年11月)。在上述两个季节中,我们注意到RSV检出率存在年龄组相关异步性;与大流行前季节相比,幼儿中的RSV检出率保持相似(或甚至有边缘性显著增加;分别为43/594,7.24%和42/556,7.55%对比292/5293,5.52%;P = 0.10和P = 0.06),而老年人中的检出率显著下降(8/好的,以下是为你补充完整并翻译后的内容:
呼吸道合胞病毒(RSV)在全球范围内给幼儿和老年人带来了巨大的发病和死亡负担。据报道,2019年冠状病毒病(COVID-19)大流行改变了RSV的流行病学特征,可能对RSV的预防和控制策略产生重要影响。我们旨在通过利用一项前瞻性呼吸道病原体监测和血清学研究收集的流行病学、分子和血清学数据,比较COVID-19大流行不同阶段与大流行前时期的RSV流行病学特征。
本研究基于2015年7月1日至2023年11月30日期间来自呼吸道病原体监测系统(RPSS)的数据,该系统是一个基于定点医院的急性呼吸道感染监测系统,由35家医院组成,代表了中国北京16个区所有年龄段的居民。通过逆转录聚合酶链反应(RT-PCR)检测RSV感染状况,并对鉴定出的RSV毒株进行基因测序和系统发育分析。我们还通过2017 - 2023年期间进行的三项血清学调查对RPSS数据进行补充,这些调查检测了血清标本中的RSV IgG水平。按日历月计算RSV检出率,并在RSV流行季节(定义为7月1日至次年6月30日)进行比较。按年份季度计算RSV IgG阳性比例,并将其与季度汇总的RSV检出率相关联,以了解人群层面感染与免疫之间的关系。
总体而言,在研究期间共收集并检测了52,931份呼吸道标本。在大流行前和大流行期间,RSV检出率在2017 - 2018季节为1.24%(94/7594),在2018 - 2019季节为2.80%(219/7824),在2022 - 2023季节为1.06%(55/5165),在2021 - 2022季节为2.98%(147/4938)。在大流行期间,ON1和BA9仍然是主要基因型;未发现新的RSV毒株。在大多数季节,RSV的传播遵循冬季季节性模式。一个例外是2020 - 2021季节,观察到全年广泛传播,可能与非药物干预(NPIs)部分放宽有关。另一个例外是2022 - 2023季节,在通常的冬季月份观察到RSV活动非常低(可能由于当地同时发生的COVID-19疫情),随后在春季出现季节性外的回升,RSV检测一直持续到研究期结束(2023年11月)。在上述两个季节中,我们注意到RSV检出率存在年龄组相关异步性;与大流行前季节相比,幼儿中的RSV检出率保持相似(或甚至有边缘性显著增加;分别为43/594,7.24%和42/556,7.55%对比292/5293,5.52%;P = 0.10和P = 0.06),而老年人中的检出率显著下降(8/1779,0.45%和3/2021,0.15%对比160/10,348,1.55%;两次比较P < 0.001)。血清学调查结果显示,与大流行前季节相比,2022 - 2023季节RSV IgG阳性率显著下降(9.32%,29/311对比20.16%,100/496;P < 0.001);在大流行前和大流行期间,老年人的RSV IgG阳性率均显著高于幼儿(P值< 0.001)。
我们的研究记录了RSV检测轨迹以及NPIs严格程度的变化、测量的IgG阳性率和当地COVID-19疫情。研究结果表明,接触模式、免疫动态和SARS-CoV-2感染在塑造不同年龄人群的RSV疫情中相互作用。这些发现为RSV传播模式的潜在驱动因素提供了新见解,并对RSV预防和控制策略具有重要意义。
高素质公共卫生专业人员发展项目、首都健康改善与研究基金以及公共卫生人员培训支持项目。